San Diego-based Celladon, which raised $43 million in February to advance development of a gene therapy treatment for heart disease, has extended the round with an additional $10 million, according to a statement yesterday. The company’s lead drug candidate is intended to restore a key enzyme for a healthy heart.
The extension added two new investors, MPM Capital and LSP Life Sciences Partners, to a group of new and existing investors that includes Lundbeckfond Ventures, Novartis Venture Funds, Hambrecht and Quist Capital Management, Pfizer Venture Investors, GBS Venture Partners, Enterprise Partners Venture Capital, Johnson & Johnson Development, and Venrock. As part of the deal, MPM Capital’s Todd Foley and LSP’s Fouad Azzam are joining Celladon’s board.
The company also plans to establish a subsidiary in The Netherlands to manage its European activities.
The funding raised by Celladon this year tops more than $61 million invested in the startup before 2012. Celladon was founded in 2004.
By posting a comment, you agree to our terms and conditions.